EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

An assessment of time toxicity in patients receiving [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer

Zachary Scharf iD, Miguel Muniz iD, Elizabeth Tchitchkan iD, Avina Rami iD, Praful Ravi, Jacob J Orme iD, Ali Tarhini iD, Heather A Jacene iD, Daniel Sentana-Lledo iD, Daniel S Childs iD

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag327 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, 2026. Verfasst von Zachary Scharf und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, United States. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Dipeptides, Heterocyclic Compounds, 1-Ring, Lutetium. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NIH HHS, Vranos Family Foundation Career Development Award in Prostate Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background [177Lu]Lu-PSMA-617 (LuPSMA) improves survival and quality of life in men with metastatic castration-resistant prostate cancer but requires substantial healthcare involvement. Our analysis evaluated the time toxicity associated with LuPSMA, representing the first dedicated radioligand time toxicity assessment. Materials and Methods We conducted a multi-institutional retrospective study of patients initiating LuPSMA between April 2022 and March 2023. Patients were followed from first LuPSMA administration until 3 months after the final cycle, initiation of new systemic therapy, or death. Time toxicity was quantified as healthcare contact days during the at-risk interval. Associations with baseline characteristics were evaluated using negative binomial regression models. Univariate and multivariable models were performed.

Results

The median age of 135 patients included in the study was 69 years, and the median prior systemic therapies was 4. Patients completed a median of 5 LuPSMA cycles over 7.6 months. Median healthcare contact days were 20 (IQR, 15-28), representing 9.5% (IQR, 6.4-13.9) of at-risk days. Fifteen patients (11%) experienced high time toxicity (>1 contact day per 5 days), while 42 (31%) had low time toxicity (≤1 contact day per 14 days). Among the 57 patients who received both cycle 1 and cycle 6, the mean per cycle healthcare contact days were 4 and 3.6, respectively (paired Wilcoxon signed-rank test, P = .04). Routine oncology visits comprised 32.7% of contact days, compared with 8.8% from hospitalizations. Lower baseline hemoglobin was independently associated with greater time toxicity (RR = 0.87; 95% CI, 0.79-0.96; P = .004).

Conclusion

In heavily pretreated patients, LuPSMA demonstrated relatively low time toxicity, supporting it as a time-efficient therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantDipeptidesHeterocyclic Compounds, 1-RingLutetiumRadiopharmaceuticalsHumansMaleAgedRetrospective StudiesMiddle AgedRadioisotopesNeoplasm MetastasisQuality of LifeProstate-Specific Antigen

Stichwörter der Autor:innen

LuPSMAradioligandradiopharmaceuticalstheranosticstime toxicity

Substanzen

DipeptidesHeterocyclic Compounds, 1-RingLutetiumRadiopharmaceuticalsRadioisotopesLutetium-177PSMA-617Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, United States.
  • Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, United States.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States.
  • Department of Internal Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States.
  • Department of Imaging, Dana-Farber Cancer Institute, Boston, MA 02215, United States.

ORCID-Profile: Zachary Scharf, Miguel Muniz, Elizabeth Tchitchkan, Avina Rami, Jacob J Orme, Ali Tarhini, Heather A Jacene, Daniel Sentana-Lledo, Daniel S Childs

Förderung

  • NCATS NIH HHS
  • NIH HHS
  • Vranos Family Foundation Career Development Award in Prostate Cancer
  • National Center for Advancing Translational Sciences
  • National Institutes of Health

Zitieren

APA

Scharf, Z., Muniz, M., Tchitchkan, E., Rami, A., Ravi, P., Orme, J. J., Tarhini, A., Jacene, H. A., Sentana-Lledo, D., & Childs, D. S. (2026). An assessment of time toxicity in patients receiving [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyag327

Vancouver

Scharf Z, Muniz M, Tchitchkan E, Rami A, Ravi P, Orme JJ, et al. An assessment of time toxicity in patients receiving [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer. The Oncologist. 2026. doi:10.1093/oncolo/oyag327

BibTeX
@article{Scharf2026,
  author = {Scharf, Zachary and Muniz, Miguel and Tchitchkan, Elizabeth and Rami, Avina and Ravi, Praful and Orme, Jacob J and Tarhini, Ali and Jacene, Heather A and Sentana-Lledo, Daniel and Childs, Daniel S},
  title = {An assessment of time toxicity in patients receiving [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag327}
}
Kostenlos starten →